Shots: In H1’21, Celltrion plans to initiate P-III trial for CT-P41 and is expected to commercialize in Feb 2025 when Amgen’s patents for Prolia expire in the US Celltrion is […]readmore
Tags : P-I trial
Shots: The companies jointly enter into P-I trial evaluating the clinical benefits, combining immune stimulator, Immuntep’s eftilagimod alpha (“efti” or “IMP321”), with Merck and Pfizer’s avelumab. Alliances will jointly develop […]readmore
Shots: The P-I trial is assessing WP1066 in 15 patients with relapsed brain tumor for 6 to 8mos, testing its safety and tolerability in patients at MD Anderson Cancer Centre […]readmore